Table 2.
Main characteristics of patients treated with sorafenib in the included studies
| Author | Year | Sample size (sorafenib) | Media age | Male (%) | Tumor size (cm) | HRs | Initial dose (sorafenib) | Duration (months; median and range) | Risk factors |
|---|---|---|---|---|---|---|---|---|---|
| Wang SN | 2014 | 14 | 61.43 | 92.9 | Median 6.26 ± 2.12 | UV/MV | 400 mg | 4 | MVI (78.16%) |
| Zhang W | 2014 | 32 | 51.7 | 78.1 | Median 5.7 ± 0.6 | UV/MV | 400 mg | – |
Multiple tumors (53.1%) Portal vein thrombosis (25%) TNM stage III (31.2%) |
| Bruix J | 2015 | 556 | 58 | 81 | Median 3.5 (1.0–20) | UV | 400 mg | 12.5 (2.6–35.8) | MVI (68%) |
| Antonious | 2016 | 16 | 65.5 | 81.3 | Median 7.8 (6.0–9.8) | UV | 200–400 mg | – | MVI (61.5%) |
| Li J | 2016 | 12 | 49.8 | 100 | Largest 9.8 ± 2.1 | UV | 400 mg | – |
BCLC C (100%) portal vein Thrombus (100%) |
| Xia F | 2016 | 34 | 48 | 73.5 | Media 6.4 (2.8–20.2) | MV | 400 mg | 22.9 | BCLC C (100%) |
| Chen BF | 2016 | 24 | 48 | 91.67 | Media 4.4 (0.8–10.5) | UV | 400 mg | 6 | – |
| Liao Y | 2017 | 14 | 47.4 | 78.6 | <10 (71.4%) ≥ 10 (28.6%) | UV/MV | 400 mg | 14.3 (2.6–24.2) | Tumor size |
| Zhuang L | 2017 | 27 | 48.2 | 92.6% | Media 7.8 ± 3.9 | UV/MV | 400 mg | 7.3 (5.8–8.9) | BCLC B/C |
| Huang Y | 2019 | 16 | 52.25 | 75% | ≤5 (37.5%) > 5 (62.5%) | UV/MV | 400 mg | 45.52 (1.10–70.97) | MVI |
| Wang DS | 2019 | 98 | 46.5 | 87.76 | Largest 7.91 ± 3.42 | UV | 400 mg | – | BCLC B/C |
| Zhang XP | 2019 | 147 | 47 | 87.8 | Media 6.0 (4.0–9.6) | UV | 400 mg | – | MVI |
| Sheng PC | 2020 | 49 | – | 73.4 | ≤5 (58.3%) > 5 (41.7%) | UV/MV | 400 mg | – | MVI |
HR hazard ratio